COXEN Model Picks the Best Drug for Ovarian Cancer
February 18, 2014 · No comments
University of Colorado Cancer Center and University of Virginia study used a sophisticated model of ovarian cancer genetics to match the right tumor with the right drug. Patients who were matched in this way lived an average 21 months longer than patients who were not matched.
Lung and bladder cancers have common cell-cycle biomarkers
January 29, 2014 · Comments Off
CU Cancer Center study: bladder and lung cancers are marked by shared differences in the genetics that control the cell cycle.
Study: Possible New Druggable Target in Ewing’s Sarcoma
January 21, 2014 · Comments Off
A University of Colorado Cancer Center study, recently published in the journal Oncogene, shows that downstream from the oncogenic fusion of genes EWS with FLI1 is a signaling chain that includes microRNA-22 and the gene KDM3A. By targeting these links, researchers hope to break this cancer-causing chain.
Study: Autophagy predicts which cancer cells live and die when faced with anti-cancer drugs
January 10, 2014 · Comments Off
When a tumor is treated with an anti-cancer drug, some cells die and, unfortunately, some cells tend to live. A University of Colorado Cancer Center study published in the journal Nature Cell Biology details a possible difference between the susceptible and resistant cells: the rate at which cells are able to cleanse themselves via the process known as autophagy.
Different parents, different children: Muscle-invasive and non-muscle invasive bladder cancers arise from different stem cells
December 17, 2013 · Comments Off
A CU Cancer Center study published today in the journal Stem Cells shows that progenitor cells that create dangerous, muscle-invasive bladder cancer are different than the progenitor cells that create non-muscle invasive bladder cancer. Though these two cancers grow at the same site, they are different diseases.
Study finds known lung cancer oncogenes ALK and ROS1 also drive colorectal cancer
December 17, 2013 · Comments Off
Study shows that shows that ALK and ROS1 gene rearrangements known to drive subsets of lung cancer are also present in some colorectal cancers. These results imply that drugs used to target ALK and ROS1 in lung cancer may also have applications in this subset of colorectal cancer patients.
JAMA Dermatology: Social media brings academic journals to general readers
November 14, 2013 · Comments Off
Robert Delavalle, PhD, shows a major difference between academic journals that embrace social media and those that do not.
Review of TAM family proteins shows how cell signaling drives brain cancer
November 13, 2013 · Comments Off
A University of Colorado Cancer Center review published in the journal Brain Research provides an overview of TAM family cell signaling in the central nervous system, and specifically within the cancer gioblastoma multiforme.
Researchers detail possible resistance mechanisms of colorectal cancer to bevacizumab (Avastin)
October 28, 2013 · Comments Off
A University of Colorado Cancer Center study published in the journal PLoS One shows that, like overflowing a dam, colorectal cancer may resist the drug bevacizumab (Avastin), by switching dependence from the main flow of VEGF-A to the "tributaries" of related growth factors including VEGF-C, VEGF-D and placental growth factor.
NTRK1: a new oncogene and target in lung cancer
October 28, 2013
ALK alk drug lung cancer ALL amc cancer fund American Association for Cancer Research andrew thorburn anthony elias antonio jimeno biomarkers bladder cancer breast cancer cancer grants cancer research colorado Cancer Survivorship cell signaling clinical trial colorado cancer benefit colorectal cancer crizotinib CU Cancer Center Dan Theodorescu fred hirsch funding opportunity grant head-and-neck cancer james degregori jennifer richer leukemia lung cancer lung cancer research melanoma metastasis Pancreatic cancer paul bunn prostate cancer publications rajesh agarwal ross camidge screening skin cancer tim byers university of colorado cancer center university of colorado hospital university of colorado school of medicine wells messersmith
One last reminder. Wear blue tomorrow for Dress in Blue Day! http://t.co/dNKEDueKNv
In Health Care, Choice Is Overrated. We're glad our patient got the second opinion needed. Hope others can too. http://t.co/3T9CrAj8E2
President Obama has declared March National Colorectal Cancer Awareness Month! Remember to wear blue this Friday... http://t.co/neqgyKCzAC